Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients

Novel presentational approaches were developed for reporting network meta-analysis

(2014) Sze Huey Tan et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

(2014) A. Castagna et al.   JOURNAL OF INFECTIOUS DISEASES

A sensitive HPLC–MS/MS method for the determination of dolutegravir in human plasma

(2013) Chantelle Bennetto-Hood et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

(2011) Sherene Min et al.   AIDS

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES

In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor

(2010) Masanori Kobayashi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cigarette Smoke Extract Induces CYP2B6 through Constitutive Androstane Receptor in Hepatocytes

(2010) I. Washio et al.   DRUG METABOLISM AND DISPOSITION

Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2

(2009) Shu-Feng Zhou et al.   AAPS Journal

A review of smoking cessation: potentially risky effects on prescribed medications

(2009) Susan D Schaffer et al.   JOURNAL OF CLINICAL NURSING

Confirmatory analysis for phase III population pharmacokinetics

(2009) Chuanpu Hu et al.   PHARMACEUTICAL STATISTICS